New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 22, 2014
20:56 EDTSHPG, ABBVAbbVie looks to diversify product mix with Shire offer, Bloomberg says
With AbbVie's (ABBV) $46.5B bid for Dublin based for Shire (SHPG), Richard Gonzalez, the AbbVie CEO is looking to diversify his company's product mix which is currently largely dependent on arthritis medicine Humira, says Bloomberg. Reference Link
News For ABBV;SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 21, 2014
08:10 EDTABBVEnanta says CHMP grants positive opinions of AbbVie's Viekirax + Exviera
Subscribe for More Information
08:05 EDTABBVCHMP grants positive opinions of VIEKIRAX/EXVIERA combo for Hep C
Subscribe for More Information
07:47 EDTABBVAbbVie price target raised to $72 from $65 at Morgan Stanley
Morgan Stanley raised AbbVie's price target to $72 based on greater Humira durability of U.S. revenues. The firm believes branded Humira rebates will make it more difficult for biosimilars to gain traction. The firm rates shares an Outperform.
November 19, 2014
09:28 EDTSHPGShire to establish Lexington, Massachusetts as U.S. operational headquarters
Subscribe for More Information
09:26 EDTSHPGShire appoints Poulton as interim CFO
Subscribe for More Information
07:52 EDTABBVInforma Business Information to hold a conference
Subscribe for More Information
07:09 EDTABBVJefferies to hold a conference
2014 Global London Healthcare Conference is being held in London, England on November 19-20.
07:08 EDTSHPGSangamo says study demonstrates in vivo reversal of Huntington's disease signs
Subscribe for More Information
November 18, 2014
06:39 EDTABBV, SHPGAstraZeneca: 'Hard to comment' on whether Pfizer will come back, Reuters reports
Subscribe for More Information
November 17, 2014
09:24 EDTABBVAbbVie to present data on investigational oncology compounds at ASH
AbbVie announced it will present data evaluating three investigational compounds from the company's oncology pipeline at the upcoming 56th American Society of Hematology Annual Meeting, or ASH, December 6-9. Data will be highlighted in 13 accepted abstracts, including several oral presentations detailing new trial results from the venetoclax program in acute myelogenous leukemia, elotuzumab in multiple myeloma, and duvelisib in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. Meeting abstracts are available at the ASH website, the company said.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use